Citicoline: A Candidate for Adjunct Treatment of Multiple Sclerosis

• Main Authors: Paweł Grieb, Maciej Świątkiewicz, Agnieszka Kamińska, Anselm Jünemann, Robert Rejdak, Konrad Rejdak
• Format: Article
• Language: English
• Published: MDPI AG 2021-04-01
• Series: Pharmaceuticals
• Subjects: citicoline; multiple sclerosis; demyelination; remyelination
• Online Access: https://www.mdpi.com/1424-8247/14/4/326

In remitting–relapsing multiple sclerosis (RR-MS), relapses are driven by autoreactive immune cells that enter the brain and spinal cord and damage myelin sheaths of axons in white and grey matter, whereas during remissions myelin is repaired by activated oligodendroglial cells. Disease-modifying therapies (DMTs) may either retard/attenuate myelin damage or promote/enhance/speed up myelin repair. Almost all currently approved DMTs inhibit myelin damage and are considerably toxic. Enhancement of myelin repair is considered an unmet medical need of MS patients. Citicoline, known for many years as a nootropic and neuroprotective drug and recently pronounced food supplement, has been found to be significantly efficacious in two complementary rodent models of MS, experimental autoimmune encephalomyelitis (EAE) and cuprizone-induced myelin toxicity. Moreover, citicoline treatment improves visual evoked potentials (VEPs) in glaucoma patients, which is relevant because VEP monitoring is frequently used as an indicator of remyelination in MS. Although over-the-counter availability of citicoline may impede its formal translation to the clinic of MS, evaluation of its efficacy for supporting remyelination in this disease is strongly indicated.